The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain - PubMed (original) (raw)
The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain
A Greco et al. Mol Cell Biol. 1995 Nov.
Abstract
Oncogenic rearrangements of the NTRK1 gene (also designated TRKA), encoding one of the receptors for the nerve growth factor, are frequently detected in thyroid carcinomas. Such rearrangements fuse the NTRK1 tyrosine kinase domain to 5'-end sequences belonging to different genes. In previously reported studies we have demonstrated that NTRK1 oncogenic activation involves two genes, TPM3 and TPR, both localized similarly to the receptor tyrosine kinase, on the q arm of chromosome 1. Here we report the characterization of a novel NTRK1-derived thyroid oncogene, named TRK-T3. A cDNA clone, capable of transforming activity, was isolated from a transformant cell line. Sequence analysis revealed that TRK-T3 contains 1,412 nucleotides of NTRK1 preceded by 598 nucleotides belonging to a novel gene that we have named TFG (TRK-fused gene). The TRK-T3 amino acid sequence displays, within the TFG region, a coiled-coil motif that could endow the oncoprotein with the capability to form complexes. The TRK-T3 oncogene encodes a 68-kDa cytoplasmic protein reacting with NTRK1-specific antibodies. By sedimentation gradient experiments the TRK-T3 oncoprotein was shown to form, in vivo, multimeric complexes, most likely trimers or tetramers. The TFG gene is ubiquitously expressed and is located on chromosome 3. The breakpoint producing the TRK-T3 oncogene occurs within exons of both the TFG gene and the NTRK1 gene and produces a chimeric exon that undergoes alternative splicing. Molecular analysis of the NTRK1 rearranged fragments indicated that the chromosomal rearrangement is reciprocal and balanced and involves loss of a few nucleotides of germ line sequences.
Similar articles
- Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes.
Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA. Greco A, et al. Genes Chromosomes Cancer. 1997 Jun;19(2):112-23. Genes Chromosomes Cancer. 1997. PMID: 9172002 - Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene.
Greco A, Fusetti L, Miranda C, Villa R, Zanotti S, Pagliardini S, Pierotti MA. Greco A, et al. Oncogene. 1998 Feb 12;16(6):809-16. doi: 10.1038/sj.onc.1201596. Oncogene. 1998. PMID: 9488046 - A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.
Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA. Butti MG, et al. Genomics. 1995 Jul 1;28(1):15-24. doi: 10.1006/geno.1995.1100. Genomics. 1995. PMID: 7590742 - The trk family of oncogenes and neurotrophin receptors.
Lamballe F, Klein R, Barbacid M. Lamballe F, et al. Princess Takamatsu Symp. 1991;22:153-70. Princess Takamatsu Symp. 1991. PMID: 1844238 Review. - Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas.
Pierotti MA, Bongarzone I, Borrello MG, Mariani C, Miranda C, Sozzi G, Greco A. Pierotti MA, et al. J Endocrinol Invest. 1995 Feb;18(2):130-3. doi: 10.1007/BF03349721. J Endocrinol Invest. 1995. PMID: 7629380 Review. No abstract available.
Cited by
- TFG regulates secretory and endosomal sorting pathways in neurons to promote their activity and maintenance.
Peotter JL, Pustova I, Lettman MM, Shatadal S, Bradberry MM, Winter-Reed AD, Charan M, Sharkey EE, Alvin JR, Bren AM, Oie AK, Chapman ER, Salamat MS, Audhya A. Peotter JL, et al. Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2210649119. doi: 10.1073/pnas.2210649119. Epub 2022 Sep 26. Proc Natl Acad Sci U S A. 2022. PMID: 36161950 Free PMC article. - TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
Kummar S, Lassen UN. Kummar S, et al. Target Oncol. 2018 Oct;13(5):545-556. doi: 10.1007/s11523-018-0590-1. Target Oncol. 2018. PMID: 30276762 Review. - Role of STAT3 in in vitro transformation triggered by TRK oncogenes.
Miranda C, Fumagalli T, Anania MC, Vizioli MG, Pagliardini S, Pierotti MA, Greco A. Miranda C, et al. PLoS One. 2010 Mar 3;5(3):e9446. doi: 10.1371/journal.pone.0009446. PLoS One. 2010. PMID: 20209132 Free PMC article. - Genetics and epigenetics of sporadic thyroid cancer.
Vu-Phan D, Koenig RJ. Vu-Phan D, et al. Mol Cell Endocrinol. 2014 Apr 5;386(1-2):55-66. doi: 10.1016/j.mce.2013.07.030. Epub 2013 Aug 8. Mol Cell Endocrinol. 2014. PMID: 23933154 Free PMC article. Review. - ced-4 and proto-oncogene tfg-1 antagonistically regulate cell size and apoptosis in C. elegans.
Chen L, McCloskey T, Joshi PM, Rothman JH. Chen L, et al. Curr Biol. 2008 Jul 22;18(14):1025-33. doi: 10.1016/j.cub.2008.06.065. Curr Biol. 2008. PMID: 18635357 Free PMC article.
References
- Cell. 1986 Jun 20;45(6):895-904 - PubMed
- Nature. 1986 Feb 27-Mar 5;319(6056):743-8 - PubMed
- Nucleic Acids Res. 1987 Oct 26;15(20):8125-48 - PubMed
- Science. 1988 Jun 17;240(4859):1648-52 - PubMed
- Mol Cell Biol. 1989 Jan;9(1):24-33 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous